NasdaqGM - Nasdaq Real Time Price USD
Neurogene Inc. (NGNE)
14.61
-0.39
(-2.60%)
As of 2:58:07 PM EDT. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 2 | 2 |
| Avg. Estimate | -0.89 | -0.93 | -3.82 | -3.96 |
| Low Estimate | -0.89 | -0.93 | -3.93 | -4.6 |
| High Estimate | -0.89 | -0.93 | -3.7 | -3.33 |
| Year Ago EPS | -- | -- | -4.28 | -3.82 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 6 | 4 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | 92k | -- | 925k | -- |
| Sales Growth (year/est) | -100.00% | 0.00% | -100.00% | 0.00% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -1.03 | -1.22 | -1.13 | -0.92 |
| EPS Actual | -1.09 | -1.19 | -0.99 | -1.08 |
| Difference | -0.06 | 0.03 | 0.14 | -0.16 |
| Surprise % | -5.62% | 2.59% | 12.26% | -17.39% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.89 | -0.93 | -3.82 | -3.96 |
| 7 Days Ago | 0 | 0 | -3.82 | -4.6 |
| 30 Days Ago | 0 | 0 | -3.7 | -4.6 |
| 60 Days Ago | 0 | 0 | -3.9 | 0 |
| 90 Days Ago | 0 | 0 | -3.9 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | 1 | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| NGNE | -- | -- | 10.86% | -3.93% |
| S&P 500 | 13.06% | 3.09% | 8.02% | 13.74% |
Upgrades & Downgrades
| Maintains | BMO Capital: Outperform to Outperform | 4/14/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/25/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/25/2024 |
| Maintains | BMO Capital: Outperform to Outperform | 11/20/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/19/2024 |
| Maintains | Stifel: Buy to Buy | 11/12/2024 |
Related Tickers
TSHA Taysha Gene Therapies, Inc.
2.1250
+1.19%
LXEO Lexeo Therapeutics, Inc.
2.8000
-6.69%
DYN Dyne Therapeutics, Inc.
11.53
+2.08%
ALSEN.PA Sensorion SA
0.4000
+2.30%
MBX MBX Biosciences, Inc.
10.86
-7.30%
DSGN Design Therapeutics, Inc.
3.4500
-1.99%
SRRK Scholar Rock Holding Corporation
30.70
-0.94%
KRRO Korro Bio, Inc.
15.45
+0.29%
TRVI Trevi Therapeutics, Inc.
6.65
+0.68%
MLYS Mineralys Therapeutics, Inc.
14.72
-5.70%